ADD/ADHD

Top Story

Low-income children with chronic conditions at risk for significant costs without CHIP renewal

May 12, 2017

Low-income children with chronic conditions and their families could experience drastic cost increases for health care as much as $233 to $2,472 in annual expenditures, depending on income levels and individual needs if the Children’s Health Insurance Program is not renewed and the families are switched to Marketplace health insurance plans.

“Prior evaluations have suggested that Marketplace plans overall offer less generous protections against high out-of-pocket expenses when compared to [Children’s Health Insurance Program (CHIP)] plans,” Alon Peltz, MD, MBA, a postdoctoral fellow at the Yale School of Medicine, and colleagues wrote. “In 2015, the secretary of health and human services, in conducting a statutorily required review of Marketplace plans for children’s coverage, declared that they were not comparable to CHIP plans in providing coverage for children’s services.”

Behind the label: ADHD over 30 years

Infectious Diseases in Children, May 2017
To mark our 30th anniversary, Infectious Diseases in Children will be examining some of the chronic conditions and infectious diseases that have impacted pediatric
Meeting News

Exposure to racism linked to higher rates of depression, ADHD in children

May 5, 2017
Children who experienced racial discrimination were more likely to exhibit anxiety and depression, as well as an increased risk for attention deficit/hyperactivity

AEVI-001 effective for adolescents with ADHD, contactin-4 mutation

May 1, 2017
Aevi Genomic Medicine recently presented updated responder data from the SAGA trial of AEVI-001, an oral nonstimulant, for adolescent ADHD. “The SAGA trial…
CME Article

Practical Guide to ADHD Pharmacotherapy

Psychiatric Annals, April 2010, Volume 40 Issue 4
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder, occurring in approximately 8% of…
More »
CME

Pediatric Rheumatology: June 2015

Keck School of Medicine of USC and Pediatric Annals

Of all the areas of pediatric practice, none can seem more daunting or require a higher index of suspicion than…
More »
Featured
American Academy of Allergy, Asthma & Immunology Annual Meeting

American Academy of Allergy, Asthma & Immunology Annual Meeting

Video
Meeting News Coverage

VIDEO: Expert discusses how to screen, diagnose and treat ADHD in preschool-aged children

September 14, 2015
More »
In the Journals

Low-income children with chronic conditions at risk for significant costs without CHIP renewal

May 12, 2017
Low-income children with chronic conditions and their families could experience drastic cost increases for health care as much as

Behind the label: ADHD over 30 years

Infectious Diseases in Children, May 2017
To mark our 30th anniversary, Infectious Diseases in Children will be examining some of the chronic conditions and infectious diseases that have

Meeting News

Exposure to racism linked to higher rates of depression, ADHD in children

May 5, 2017
Children who experienced racial discrimination were more likely to exhibit anxiety and depression, as well as an increased risk for attention

AEVI-001 effective for adolescents with ADHD, contactin-4 mutation

May 1, 2017
Aevi Genomic Medicine recently presented updated responder data from the SAGA trial of AEVI-001, an oral nonstimulant, for adolescent ADHD. …

Dasotraline improves ADHD outcomes in the classroom

April 28, 2017
Recent findings indicated dasotraline, a dopamine and norepinephrine reuptake inhibitor, significantly improved ADHD outcomes in the classroom among…

Vyvanse available as chewable tablet

April 20, 2017
Shire recently announced that Vyvanse is now available in the U.S. as a chewable tablet. “Vyvanse chewable tablets will offer an option to…

AEVI-001 fails to meet efficacy endpoint for ADHD

March 23, 2017
AEVI-001, an oral non-stimulant, did not meet its primary efficacy endpoint for ADHD, but did exhibit an encouraging trend in improvement at its…

In the Journals

ADHD, asthma rates significantly higher among impoverished children

March 3, 2017
Parent-reported lifetime prevalence and comorbidity of asthma, attention deficit/hyperactivity disorder and autism spectrum disorder in children

FDA receives resubmitted NDA for SHP465 for ADHD

January 24, 2017
Shire recently announced that the FDA acknowledged receipt of a class 2 resubmission of a New Drug Application for SHP465, a triple-bead mixed…

Dasotraline effective for ADHD in children

January 20, 2017
Sunovion Pharmaceuticals recently announced dasotraline, a dopamine and norepinephrine reuptake inhibitor, significantly improved ADHD in children…

More Headlines »
Advertisement
Advertisement